Abstract
For over 25 years, the standard of care for resectable pancreatic adenocarcinoma has been upfront surgery followed by delivery of post-operative therapy. Until recently however, there has been no consensus as what constituted a standard adjuvant regimen. Data from large phase III studies now support single agent gemcitabine, administered over 6 cycles, as standard. Nevertheless, the overall survival of patients undergoing upfront surgical resection followed by adjuvant therapy remains poor, with no significant improvements in median, or long term survival over the last 3 decades. Surgery as the first intervention for potentially curative pancreatic cancer has some distinct disadvantages and neoadjuvant therapy provides a mechanism to better select patients for subsequent surgical intervention. Current data suggest this approach spares patients from a morbid surgical procedure when it will be of no benefit and improves outcomes for those who do undergo surgery. Furthermore, with the increasing recognition of borderline resectable pancreatic cancer, neoadjuvant treatment should be considered as alternative to upfront surgery for this distinct clinical entity. This has the potential to maximize the chances of a margin-negative resection and minimize the number of patients harboring aggressive disease from undergoing a fruitless surgical procedure. Importantly, as the number of targeted agents available for clinical use expands, more rational, personalized neoadjuvant therapies may emerge.
Keywords: Pancreatic cancer, surgery, adjuvant therapy, preoperative therapy, neoadjuvant therapy, chemotherapy, chemoradiation, molecular therapy, Adenocarcinoma, Resectable
Current Drug Targets
Title:Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Volume: 13 Issue: 6
Author(s): Robert A. Wolff
Affiliation:
Keywords: Pancreatic cancer, surgery, adjuvant therapy, preoperative therapy, neoadjuvant therapy, chemotherapy, chemoradiation, molecular therapy, Adenocarcinoma, Resectable
Abstract: For over 25 years, the standard of care for resectable pancreatic adenocarcinoma has been upfront surgery followed by delivery of post-operative therapy. Until recently however, there has been no consensus as what constituted a standard adjuvant regimen. Data from large phase III studies now support single agent gemcitabine, administered over 6 cycles, as standard. Nevertheless, the overall survival of patients undergoing upfront surgical resection followed by adjuvant therapy remains poor, with no significant improvements in median, or long term survival over the last 3 decades. Surgery as the first intervention for potentially curative pancreatic cancer has some distinct disadvantages and neoadjuvant therapy provides a mechanism to better select patients for subsequent surgical intervention. Current data suggest this approach spares patients from a morbid surgical procedure when it will be of no benefit and improves outcomes for those who do undergo surgery. Furthermore, with the increasing recognition of borderline resectable pancreatic cancer, neoadjuvant treatment should be considered as alternative to upfront surgery for this distinct clinical entity. This has the potential to maximize the chances of a margin-negative resection and minimize the number of patients harboring aggressive disease from undergoing a fruitless surgical procedure. Importantly, as the number of targeted agents available for clinical use expands, more rational, personalized neoadjuvant therapies may emerge.
Export Options
About this article
Cite this article as:
A. Wolff Robert, Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas, Current Drug Targets 2012; 13 (6) . https://dx.doi.org/10.2174/138945012800564086
DOI https://dx.doi.org/10.2174/138945012800564086 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
Current Gene Therapy Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science MicroRNAs in Prostate Cancer Following Radiotherapy: Towards Predicting Response to Radiation Treatment
Current Medicinal Chemistry PARP Inhibitor Development for Systemic Cancer Targeting
Anti-Cancer Agents in Medicinal Chemistry Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses
Current Pharmaceutical Design Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Electrochemical Cell-based Biosensors for Biomedical Applications
Current Topics in Medicinal Chemistry The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry Cell to Cell Spreading of Misfolded Proteins as a Therapeutic Target in Motor Neuron Disease
Current Medicinal Chemistry Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease
Current Neuropharmacology Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy